Octreotide is generally applied across clinical settings marked by symptoms related to systemic imbalance of certain internal hormones and peptides. Its primary role is to provide essential symptomatic and hormonal management, rather than acting as a traditional pain reliever or anti-infective agent. It is considered relevant for chronic conditions like Acromegaly and the symptom management of specific neuroendocrine tumors, including Carcinoid Syndrome and VIPomas.

This medication helps address groups of symptoms that may appear suddenly or intensify over time, particularly in patients with metastatic neuroendocrine tumors. It is used for managing symptoms that may become intense or disruptive, such as recurrent, intense flushing episodes and profuse, watery secretory diarrhea. Furthermore, in Acromegaly, Octreotide is applied in contexts where additional support for hormonal management is needed, assisting with maintaining functional stability and contributing to easing the overall symptom load associated with physical changes. This offers symptomatic relief that helps patients cope more steadily with difficult episodes.

Quick Facts: Therapeutic Focus

Regulatory References

1. NIH MedlinePlus overview

Eligibility Map: Who Can and Cannot Use Octreotide — Official Regulatory Information

Eligibility Scope

Age-Related Eligibility Rules: Use in adults is standard. While no adjustment is necessary for older adults based on age alone, caution is warranted due to the potential for co-existing renal, hepatic, or cardiac conditions.

Condition-Specific Eligibility Rules: Eligibility is conditional for patients with hepatic impairment (cirrhosis) or severe renal impairment; the label mandates dose adjustment due to altered drug clearance. Close monitoring is required for patients with diabetes, insulinoma, pre-existing cardiac issues, or gallbladder disease.

Pregnancy and Lactation Eligibility Status: Use in pregnancy is restricted, permitted only if clearly needed. The risk to the infant during lactation (breastfeeding) cannot be excluded. Premenopausal women must be advised to use adequate contraception.

Connection to the Overall Eligibility Profile

Regulatory documents define a single absolute contraindication (hypersensitivity) and then define conditional eligibility for specific patient subgroups based on physiological and demographic status. The profile imposes explicit restrictions, such as dose adjustments for impaired organ function and mandated monitoring for metabolic or cardiac risks, to govern use in otherwise eligible populations.

Interactions with other medicines and products

Octreotide has officially documented interaction patterns structured around its effects on endocrine systems and the metabolism of co-administered substances. Regulatory labels establish which combinations are restricted and which require specific administrative conditions.

Interaction Classifications

Administration and Conditions

Official documents mandate specific timing rules for diagnostic procedures; for instance, a washout period of 28 days is required for the long-acting formulation before certain somatostatin receptor-targeted imaging agents. Interactions are also noted in specific populations: elimination is prolonged in patients with severe renal impairment, and the half-life may be increased in those with hepatic impairment. Octreotide is associated with depressed Vitamin B12 levels and may alter the absorption of dietary fats.

Direct Receptor Agonism and Secretion Suppression

Octreotide acts as an agonist of the Somatostatin Receptors (SSTRs), primarily the SSTR2 subtype. Activation of these receptors triggers the inhibitory mathbfGmathbfi/mathbfo protein pathway, which inhibits adenylyl cyclase (AC) activity and reduces intracellular calcium levels. This molecular cascade inhibits cellular exocytosis (the mechanism of release) in secretory cells, leading to a systemic suppression of hormone and peptide release.

Alteration of Splanchnic Blood Flow and Fluid Transport

Octreotide influences regional hemodynamics by inhibiting the release of vasodilatory mediators like Nitric Oxide (NO) in the visceral vasculature. This action results in localized vasoconstriction in the splanchnic area, which alters regional hemodynamics. Concurrently, its anti-secretory effect on the gut wall increases the absorption of water and electrolytes across the intestinal barrier.

Anti-Proliferative Signaling

Octreotide also engages SSTR-linked pathways that influence cell fate, acting via second messenger systems independent of the main anti-secretory cascade. This mechanism modulates cellular growth and leads to the induction of apoptosis ( programmed cell death) in cells that over-express the receptors.

Octreotide usage is defined by its formulation, which dictates the required route of administration, frequency, and preparation. The drug is supplied as an immediate-release solution for subcutaneous (SC) or intravenous (IV) injection, a long-acting suspension (LAR) for deep intramuscular (IM) injection, and an oral delayed-release capsule.

Administration and Dosing Schedules

The immediate-release solution is used for initial dose establishment; patients switching to the LAR formulation must continue the short-acting SC injection for at least two weeks after the first intramuscular dose to ensure consistent therapeutic levels are achieved.

Specific Administration Conditions and Adjustments

Proper use dictates strict adherence to administration conditions. The oral capsule must be taken on an empty stomach, one hour before or two hours after a meal, and must be swallowed whole. The LAR suspension requires reconstitution after reaching room temperature and is administered immediately via deep IM injection, with required rotation of the injection site (e.g., between the left and right gluteal muscle). Initial dosing must be modified in certain patient populations; for example, a lower starting dose of LAR (10 mg every four weeks) is specified for those with advanced hepatic or renal impairment. Dose adjustments for the LAR product are typically considered only after the initial two to three months of treatment.

Research Evidence / Overview of Studies for Октреотид

Research Evidence for Managing Acromegaly

Research for Acromegaly includes controlled clinical trials and long-term observational studies involving adult patients diagnosed with a Growth Hormone (GH)-secreting tumor. Researchers explored how both the short-acting injectable and the long-acting release (LAR) formulations were studied in the disease. The measured outcomes included key laboratory values, specifically assessing the change in GH and IGF-1 levels, which are biomarkers tracked in the condition. Studies also included an assessment of changes in pituitary tumor size using imaging.

Studies reported patterns of changes in the high GH and IGF-1 levels in the observed populations. Published scientific reviews described patterns of tumor size reduction based on aggregated data from multiple trials. What remains uncertain is that the evidence for the drug's activity on tumor size was initially gathered from open-label trials, and data for patients who have never been treated with any similar medication remain less established in the evidence base for newer forms.

Research Evidence for Symptom Control in Neuroendocrine Tumor Syndromes

Research exploring severe symptoms from Neuroendocrine Tumor Syndromes, such as Carcinoid Syndrome and VIPomas, was evaluated through controlled clinical trials. Studies focused on populations with functioning tumors characterized by fluctuating manifestations. The research was relevant in trials assessing short-term symptom patterns and examined outcomes related to physical discomfort. Studies reported patterns in the observed populations, particularly for diarrhea and flushing episodes.

Research Evidence for Anti-Tumor Effects in Neuroendocrine Tumors (NETs)

Research examining anti-proliferative activity of Octreotide, particularly the long-acting formulation, was evaluated through Randomized Controlled Trials (RCTs) against a placebo. These studies included adult patients with advanced (metastatic), well-differentiated NETs, often originating from the midgut. A large Phase III RCT reported differences in the measured time until tumor progression was observed in the study group compared to the control group. The generalizability of these findings to tumors originating in other areas may be limited.

Long-Term Studies and Follow-Up Duration

Studies for both acromegaly and neuroendocrine tumors have often included Long-Term Extension Phases to monitor the durability of the observed responses. While long-term data show patterns related to sustained hormonal management, long-term effects on every patient group are not fully established. Variability in the evidence quality exists across studies, particularly in research areas outside of the primary endocrine uses.

Key Studies & References

1. Octreotide: MedlinePlus Drug Information

Common questions about Октреотид (FAQ)

Q: What is Октреотид used for?

A: Октреотид is a synthetic medication that is chemically similar to the naturally occurring hormone somatostatin. It is medically indicated for the management of certain symptoms associated with carcinoid tumors and VIPomas. It is also used to treat certain complications following surgery of the pancreas.

Q: How does Октреотид work in the body?

A: Research suggests that Октреотид binds to specific receptors in the body, which may lead to a reduction in the secretion of certain hormones, such as growth hormone and some gastrointestinal peptides. This mechanism is believed to be related to its therapeutic effect in managing symptoms of certain tumors.

Q: Are there important side effects associated with Октреотид?

A: As with many medications, Октреотид may be associated with side effects. Commonly reported effects in clinical studies include gastrointestinal issues like diarrhea and abdominal discomfort. Gallstone formation has also been observed in some individuals receiving the treatment. Any concerns regarding potential side effects should be discussed with a healthcare professional.

Q: Can Октреотид be used for all types of tumors?

A: Октреотид is specifically approved for the management of certain symptoms associated with carcinoid tumors and VIPomas. Its use is limited to the conditions for which it has been officially indicated and studied. Its effectiveness in other tumor types is generally not supported by current indications.

How to Store and Dispose of Octreotide

The storage of Octreotide is strictly governed by regulatory requirements to ensure the product's stability. Unopened vials or ampoules must be stored in the refrigerator at a temperature range of 2 C to 8 C (36 F to 46 F).

Storage Requirements

• Do not freeze the product; freezing necessitates disposal.
• Store in the original container or carton to maintain protection from light.
• Opened multidose vials typically have a limited shelf-life, such as 14 days, when stored under refrigeration.
• Before use, the unopened vial should be allowed to reach room temperature.

Child Safety and Disposal

All Octreotide preparations must be kept out of the sight and reach of children.

Disposal of any unused or expired product must strictly follow local pharmaceutical waste regulations. The medication should not be disposed of using household garbage or wastewater unless explicitly permitted by local authorities.